

INNOVUS PHARMACEUTICALS, INC.
Form 10-Q
August 14, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period ended June 30, 2017

or

Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act.

For the transition period from ____ to ____.

Commission File Number: 000-52991

INNOVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Nevada	90-0814124
(State or Other Jurisdiction of Incorporation or Organization)	(IRS Employer Identification No.)

9171 Towne Centre Drive, Suite 440, San Diego, CA	92122
(Address of Principal Executive Offices)	(Zip Code)

858-964-5123
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant Rule 405 of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a nonaccelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act (Check one):

Edgar Filing: INNOVUS PHARMACEUTICALS, INC. - Form 10-Q

Large accelerated filer	Accelerated filer
Non-accelerated filer	Smaller reporting company
Emerging growth company	

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
No

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

As of August 11, 2017, the registrant had 151,303,679 shares of common stock outstanding.

TABLE OF CONTENTS

	Page
<u>PART I — FINANCIAL INFORMATION</u>	
<u>Item 1. Financial Statements</u>	1
<u>Condensed Consolidated Balance Sheets at June 30, 2017 (Unaudited) and December 31, 2016</u>	1
<u>Condensed Consolidated Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2017 and 2016</u>	2
<u>Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2017 and 2016</u>	3
<u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u>	5
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	26
<u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u>	34
<u>Item 4. Controls and Procedures</u>	34
<u>PART II—OTHER INFORMATION</u>	
<u>Item 1. Legal Proceedings</u>	35
<u>Item 1A. Risk Factors</u>	35
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	35
<u>Item 3. Defaults Upon Senior Securities</u>	35
<u>Item 4. Mine Safety Disclosures</u>	35
<u>Item 5. Other Information</u>	35
<u>Item 6. Exhibits</u>	35
<u>Signatures</u>	36
<u>Index to Exhibits</u>	37

Table of ContentsINNOVUS PHARMACEUTICALS, INC.
Condensed Consolidated Balance Sheets

	June 30, 2017	December 31, 2016
	(Unaudited)	
ASSETS		
Assets:		
Cash	\$1,824,633	\$829,933
Accounts receivable, net	21,148	33,575
Prepaid expense and other current assets	394,273	863,664
Inventories	586,455	599,856
Total current assets	2,826,509	2,327,028
Property and equipment, net	32,197	29,569
Deposits	14,958	14,958
Goodwill	952,576	952,576
Intangible assets, net	4,588,049	4,903,247
Total assets	\$8,414,289	\$8,227,378
 LIABILITIES AND STOCKHOLDERS' EQUITY		
Liabilities:		
Accounts payable and accrued expense	\$1,256,551	\$1,210,050
Accrued compensation	1,540,224	767,689
Deferred revenue and customer deposits	46,769	11,000
Accrued interest payable	20,587	47,782
Derivative liabilities – embedded conversion features	-	319,674
Derivative liabilities – warrants	90,206	164,070
Contingent consideration	75,699	170,015
Current portion of notes payable, net of debt discount of \$104,788 and \$216,403, respectively	819,252	626,610
Convertible debentures, net of debt discount of \$0 and \$845,730, respectively	-	714,192
Total current liabilities	3,849,288	4,031,082
Accrued compensation – less current portion	1,036,315	1,531,904

Edgar Filing: INNOVUS PHARMACEUTICALS, INC. - Form 10-Q

Notes payable, net of current portion and debt discount of \$0 and \$468, respectively	-	54,517
Contingent consideration – less current portion	1,484,064	1,515,902
Total non-current liabilities	2,520,379	3,102,323
Total liabilities	6,369,667	7,133,405
Commitments and contingencies		
Stockholders' equity:		
Preferred stock: 7,500,000 shares authorized, at \$0.001 par value, no shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	-	-
Common stock: 292,500,000 shares authorized, at \$0.001 par value, 151,027,774 and 121,694,293 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	151,028	121,694
Additional paid-in capital	34,709,180	30,108,028
Accumulated deficit	(32,815,586)	(29,135,749)
Total stockholders' equity	2,044,622	1,093,973
Total liabilities and stockholders' equity	\$8,414,289	\$8,227,378

See accompanying notes to these condensed consolidated financial statements.

Table of Contents

INNOVUS PHARMACEUTICALS, INC.
Condensed Consolidated Statements of Operations
(Unaudited)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2017	2016	2017	2016
Net revenue:				
Product sales, net	\$2,031,157	\$1,019,520	\$4,208,447	\$1,243,983
License revenue	7,500	-	7,500	1,000
Net revenue	2,038,657	1,019,520	4,215,947	1,244,983
Operating expense:				
Cost of product sales	408,579	262,934	849,055	383,057
Research and development	15,063	3,892	18,246	3,892
Sales and marketing	1,555,736	249,515	3,243,087	285,011
General and administrative	1,182,235	945,572	2,886,898	2,233,309
Total operating expense	3,161,613	1,461,913	6,997,286	2,905,269
Loss from operations	(1,122,956)	(442,393)	(2,781,339)	(1,660,286)
Other income (expense):				
Interest expense	(110,130)	(1,860,399)	(667,609)	(2,251,250)
Loss on extinguishment of debt	-	-	(304,828)	-
Other income (expense), net	(206)	111	(822)	1,876
Fair value adjustment for contingent consideration	98,979	(16,750)	126,154	(22,334)
Change in fair value of derivative liabilities	3,463	(2,040,909)	(48,193)	(1,983,315)
Total other expense, net	(7,894)	(3,917,947)	(895,298)	(4,255,023)
Loss before provision for income taxes	(1,130,850)	(4,360,340)	(3,676,637)	(5,915,309)
Provision for income taxes	3,200	-	3,200	-
Net loss	\$(1,134,050)	\$(4,360,340)	\$(3,679,837)	\$(5,915,309)
Net loss per share of common stock – basic and diluted	\$(0.01)	\$(0.05)	\$(0.02)	\$(0.08)
Weighted average number of shares of common stock outstanding – basic and diluted	159,997,395	85,395,846	147,617,064	70,271,333

See accompanying notes to these condensed consolidated financial statements.

Table of Contents

INNOVUS PHARMACEUTICALS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

	For the Six Months Ended June 30,	
	2017	2016
Cash flows from operating activities:		
Net loss	\$(3,679,837)	\$(5,915,309)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:		
Depreciation	5,420	7,370
Allowance for doubtful accounts	4,276	5,708
Common stock, restricted stock units and stock options issued to employees, board of directors and consultants for compensation and services	742,301	1,223,941
Loss on extinguishment of debt	304,828	-
Fair value of embedded conversion feature in convertible debentures in excess of allocated proceeds	-	938,840
Change in fair value of contingent consideration	(126,154)	22,334
Change in fair value of derivative liabilities	48,193	1,983,315
Amortization of debt discount	601,348	1,161,131
Amortization of intangible assets	315,198	335,685
Changes in operating assets and liabilities, net of acquisition amounts		
Accounts receivable	8,151	55,242
Prepaid expense and other current assets	88,452	24,964
Deposits	-	(37,460)
Inventories	13,401	32,006
Accounts payable and accrued expense	406,501	98,835
Accrued compensation	276,946	279,728
Accrued interest payable	(14,085)	56,147
Deferred revenue and customer deposits	35,769	(16,325)
Net cash (used in) provided by operating activities	(969,292)	256,152
Cash flows used in investing activities:		
Purchase of property and equipment	(8,048)	(6,565)
Cash flows from financing activities:		
Repayments of line of credit convertible debenture – related party	-	(119,000)
Proceeds from short-term loans payable	-	21,800

Edgar Filing: INNOVUS PHARMACEUTICALS, INC. - Form 10-Q

Payments on short-term loans payable	-	(180,995)
Proceeds from notes payable and convertible debentures	150,000	416,500
Payments on notes payable	(138,958)	(226,660)
Proceeds from stock option exercises	2,894	-
Financing costs in connection with convertible debentures	-	(19,000)
Proceeds from sale of common stock and warrants, net of offering costs	3,307,773	-
Payments on convertible debentures	(1,222,422)	-
Prepayment penalty on extinguishment of convertible debentures	(127,247)	-
Net cash provided by (used in) financing activities	1,972,040	(107,355)
Net change in cash	994,700	142,232
Cash at beginning of period	829,933	55,901
Cash at end of period	\$1,824,633	\$198,133

-3-

Table of Contents

Supplemental disclosures of cash flow information:

Cash paid for income taxes	\$5,600	\$-
Cash paid for interest	\$80,344	\$87,085

Supplemental disclosures of non-cash investing and financing activities:

Common stock issued for conversion of convertible debentures and accrued interest	\$350,610	\$1,515,635
Reclassification of the fair value of the embedded conversion features from derivative liability to additional paid-in capital upon conversion	\$203,630	\$2,018,565
Relative fair value of common stock issued in connection with notes payable recorded as debt discount	\$44,217	\$93,964
Proceeds from note payable paid to seller in connection with acquisition	\$-	\$300,000
Financing costs paid with proceeds from note payable	\$-	\$7,500
Cashless exercise of warrants	\$-	\$3,194
Fair value of the contingent consideration for acquisition	\$-	\$314,479
Reclassification of the fair value of the warrants from derivative liability to additional paid-in capital upon cashless exercise	\$-	\$518,224
Relative fair value of warrants issued in connection with convertible debentures recorded as debt discount	\$-	\$186,526
Relative fair value of common stock subscribed but unissued in connection with convertible debentures recorded as debt discount	\$-	\$472,814
Fair value of embedded conversion feature derivative liabilities recorded as debt discount	\$-	\$470,824
Fair value of warrants issued to placement agents in connection with convertible debentures recorded as debt discount	\$-	\$140,836
Deferred financing costs included in accounts payable and accrued expense	\$-	\$15,000
Net proceeds from convertible debentures in escrow included in restricted cash	\$-	\$1,305,000
Fair value of non-forfeitable common stock issued to consultant recorded as prepaid expense and other current assets	\$-	\$9,500
Fair value of non-forfeitable common stock issued to consultant included in accounts payable and accrued expense	\$360,000	\$-
Issuance of shares of common stock for vested restricted stock units	\$92	\$18,888
Fair value of common stock issued for prepayment of future royalties due under the CRI License Agreement included in prepaid expense and other current assets	\$44,662	\$-
Fair value of beneficial conversion feature on line of credit convertible debenture – related party	\$-	\$3,444

See accompanying notes to these condensed consolidated financial statements.

Table of Contents

INNOVUS PHARMACEUTICALS, INC.
Notes to Condensed Consolidated Financial Statements
June 30, 2017
(Unaudited)

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

Innovus Pharmaceuticals, Inc., together with its subsidiaries (collectively referred to as “Innovus”, “we”, “our”, “us” or the “Company”) is a Nevada formed, San Diego, California-based emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men’s and women’s health and respiratory diseases.

We generate revenue from 21 commercial products in the United States, including six of these commercial products in multiple countries around the world through our commercial partners. Our commercial product portfolio includes (a) Beyond Human® Testosterone Booster, (b) Beyond Human® Growth Agent, (c) Zestra® to increase female arousal and desire, (d) EjectDelay® for premature ejaculation, (e) Sensus+® for reduced penile sensitivity, (f) Zestra Glide®, (g) Vesele® for promoting sexual health, (h) Androferti® to support overall male reproductive health and sperm quality, (i) RecalMax™ for cognitive brain health, (j) Beyond Human® Green Coffee Extract, (k) Beyond Human® Vision Formula, (l) Beyond Human® Blood Sugar, (m) Beyond Human® Colon Cleanse, (n) Beyond Human® Ketones, (o) Beyond Human® Krill Oil, (p) Beyond Human® Omega 3 Fish Oil, (q) UriVarx™ for bladder health, (r) ProstaGorx™ for prostate health, (s) AllerVarx™ for management of allergy symptoms, (t) Apeaz™ indicated for arthritis pain relief, and (u) ArthriVarx™ for joint health. While we generate revenue from the sale of our commercial products, most revenue is currently generated by Vesele®, Zestra®, Zestra® Glide, RecalMax™, Sensus+®, UriVarx™, ProstaGorx™, AllerVarx™, Apeaz™, ArthriVarx™ and Beyond Human® Testosterone Booster.

Pipeline Products

FlutiCare™ (fluticasone propionate nasal spray). FlutiCare™ is our nationally branded Over-the-Counter (“OTC”) fluticasone propionate nasal spray, United States Pharmacopeia (“USP”) 50 mcg per spray, which is indicated to treat individuals with allergic rhinitis, or more commonly referred to as “allergies”. Allergic rhinitis is one of the most common ailments in the western world and is continuing to grow as there are approximately 50 million sufferers in the U.S. alone according to GlobalData. We expect to launch our FlutiCare™ OTC product in the U.S. in the fourth quarter of 2017 (see Note 3).

PEVarx™. This product is designed and tested in over 600 men to extend the length of sexual intercourse and enhance male sexual performance and stamina. We expect to launch this product in the second half of 2017.

Xyralid™. Xyralid™ is an OTC FDA monograph compliant drug containing the active drug ingredient lidocaine and indicated for the relief of the pain and symptoms caused by hemorrhoids. We expect to launch this product in the second half of 2017.

Urocis™ XR. Urocis™ XR is a proprietary extended release of Vaccinium Marcocarpon (cranberry) shown to provide 24-hour coverage in the body in connection with urinary tract infections in women. We expect to launch this product in the second half of 2017.

AndroVit™. AndroVit™ is a proprietary supplement to support overall prostate and male sexual health. AndroVit™ was specifically formulated with ingredients known to support normal prostate health and vitality and male sexual health. We expect to launch this product in the second half of 2017.

Basis of Presentation and Principles of Consolidation

The condensed consolidated balance sheet as of December 31, 2016, which has been derived from audited consolidated financial statements, and these unaudited condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly owned subsidiaries: FasTrack Pharmaceuticals, Inc., Semprae Laboratories, Inc. (“Semprae”) and Novalere, Inc. (“Novalere”). All material intercompany transactions and balances have been eliminated. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Certain information required by U.S. GAAP has been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The results for the period ended June 30, 2017, are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2017 or for any future period. Certain items have been reclassified to conform to the current year presentation.

Table of Contents

Use of Estimates

The preparation of these condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such management estimates include the allowance for doubtful accounts, sales returns and chargebacks, realizability of inventories, valuation of deferred tax assets, goodwill and intangible assets, valuation of contingent acquisition consideration, recoverability of long-lived assets and goodwill, fair value of derivative liabilities and the valuation of equity-based instruments and beneficial conversion features. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions.

Liquidity

Our operations have been financed primarily through proceeds from convertible debentures and notes payable, sales of our common stock and revenue generated from our products domestically and internationally by our partners. These funds have provided us with the resources to operate our business, sell and support our products, attract and retain key personnel and add new products to our portfolio. We have experienced net losses and negative cash flows from operations each year since our inception. As of June 30, 2017, we had an accumulated deficit of \$32,815,586 and a working capital deficit of \$1,022,779.

In March 2017, we raised net cash proceeds of \$3,307,773 from the sale of common stock and warrants in a registered public offering (see Note 7) and, in January 2017 and December 2016, we raised \$650,000 in gross proceeds from the issuance of notes payable to three investors (see Note 5). We have also issued equity instruments in certain circumstances to pay for services from vendors and consultants.

As of June 30, 2017, we had \$1,824,633 in cash. During the six months ended June 30, 2017, we had net cash used in operating activities of \$969,292. We expect that our existing capital resources, revenue from sales of our products and upcoming sales milestone payments from the commercial partners signed for our products will be sufficient to allow us to continue our operations, commence the product development process and launch selected products through at least the next 12 months. In addition, our CEO, who is also a significant shareholder, has deferred the remaining payment of his salary earned thru June 30, 2016 totaling \$1,036,315 for at least the next 12 months. Our actual needs will depend on numerous factors, including timing of introducing our products to the marketplace, our ability to attract additional international distributors for our products and our ability to in-license in non-partnered territories and/or develop new product candidates. Although no assurances can be given, we may raise additional capital through the sale of debt or equity securities to provide additional working capital, pay for further expansion and development of our business, and to meet current obligations. Such capital may not be available to us when we need it or on terms acceptable to us, if at all.

Fair Value Measurement

Our financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, derivative liabilities, contingent consideration and debt. The recorded values of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The fair values of the warrant derivative liabilities and embedded conversion feature derivative liabilities are based upon the Black Scholes Option Pricing Model ("Black-Scholes") and the Path-Dependent Monte Carlo Simulation Model calculations, respectively, and are a Level 3 measurement (see Note 8). The fair value of the contingent acquisition consideration is based upon the present

value of expected future payments under the terms of the agreements and is a Level 3 measurement (see Note 3). Based on borrowing rates currently available to us, the carrying values of the notes payable approximate their respective fair values.

We follow a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows:

Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access at the measurement date.

Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly.

Level 3 measurements are unobservable inputs.

Table of Contents

Concentration of Credit Risk, Major Customers and Segment Information

Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and accounts receivable. Cash held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation on such deposits. Accounts receivable consist primarily of sales of Zestra® to U.S. based retailers and Ex-U.S. partners. We also require a percentage of payment in advance for product orders with our larger partners. We perform ongoing credit evaluations of our customers and generally do not require collateral.

Revenues consist primarily of product sales and licensing rights to market and commercialize our products. We have no customers that accounted for 10% or more of our total net revenue during the three and six months ended June 30, 2017 and 2016 and two customers accounted for 60% of total net accounts receivable as of June 30, 2017. We had three customers that accounted for 62% of total net accounts receivable as of December 31, 2016.

Over 95% of our sales are currently within the United States and Canada. The balance of the sales are to various other countries, none of which is 10% or greater.

We operate our business on the basis of a single reportable segment, which is the business of delivering over-the-counter medicines and consumer care products for men's and women's health and respiratory diseases. Our chief operating decision-maker is the Chief Executive Officer, who evaluates us as a single operating segment.

Revenue Recognition and Deferred Revenue

We generate revenue from product sales and the licensing of the rights to market and commercialize our products.

We recognize revenue in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 605, Revenue Recognition. Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) title to the product has passed or services have been rendered; (3) price to the buyer is fixed or determinable and (4) collectability is reasonably assured.

Product Sales: We ship products directly to consumers pursuant to phone or online orders and to our wholesale and retail customers pursuant to purchase agreements or sales orders. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the seller's price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product, (3) the buyer's obligation to the seller would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the seller, (5) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer and (6) the amount of future returns can be reasonably estimated.

License Revenue: The license agreements we enter into normally generate three separate components of revenue: 1) an initial payment due on signing or when certain specific conditions are met; 2) royalties that are earned on an ongoing basis as sales are made or a pre-agreed transfer price and 3) sales-based milestone payments that are earned when cumulative sales reach certain levels. Revenue from the initial payments or licensing fee is recognized when all required conditions are met. Royalties are recognized as earned based on the licensee's sales. Revenue from the sales-based milestone payments is recognized when the cumulative revenue levels are reached. The achievement of the sales-based milestone underlying the payment to be received predominantly relates to the licensee's performance of future commercial activities. FASB ASC 605-28, Milestone Method, ("ASC 605-28") is not used by us as these milestones do not meet the definition of a milestone under ASC 605-28 as they are sales-based and similar to a royalty

and the achievement of the sales levels is neither based, in whole or in part, on our performance, a specific outcome resulting from our performance, nor is it a research or development deliverable.

Sales Allowances

We accrue for product returns, volume rebates and promotional discounts in the same period the related sale is recognized.

Our product returns accrual is primarily based on estimates of future product returns over the period customers have a right of return, which is in turn based in part on estimates of the remaining shelf-life of products when sold to customers. Future product returns are estimated primarily based on historical sales and return rates. We estimate our volume rebates and promotional discounts accrual based on its estimates of the level of inventory of our products in the distribution channel that remain subject to these discounts. The estimate of the level of products in the distribution channel is based primarily on data provided by our customers.

Table of Contents

In all cases, judgment is required in estimating these reserves. Actual claims for rebates and returns and promotional discounts could be materially different from the estimates.

We provide a customer satisfaction warranty on all of our products to customers for a specified amount of time after product delivery. Estimated return costs are based on historical experience and estimated and recorded when the related sales are recognized. Any additional costs are recorded when incurred or when they can reasonably be estimated.

The estimated reserve for sales returns and allowances, which is included in accounts payable and accrued expense, was approximately \$51,000 and \$61,000 at June 30, 2017 and December 31, 2016, respectively.

Advertising Expense

Advertising costs, which primarily includes print and online media advertisements, are expensed as incurred and are included in sales and marketing expense in the accompanying condensed consolidated statements of operations. Advertising costs were approximately \$1,253,000 and \$169,000 and \$2,611,000 and \$180,000 for the three and six months ended June 30, 2017 and 2016, respectively.

Debt Extinguishment

Any gain or loss associated with debt extinguishment is recorded in the period in which the debt is considered extinguished. Third party fees incurred in connection with a debt restructuring accounted for as an extinguishment are capitalized. Fees paid to third parties associated with a term debt restructuring accounted for as a modification are expensed as incurred. Third party and creditor fees incurred in connection with a modification to a line of credit or revolving debt arrangements are considered to be associated with the new arrangement and are capitalized.

Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding and vested but deferred RSUs during the period presented. Diluted net loss per share is computed using the weighted average number of common shares outstanding and vested but deferred RSUs during the periods plus the effect of dilutive securities outstanding during the periods. For the three and six months ended June 30, 2017 and 2016, basic net loss per share is the same as diluted net loss per share as a result of our common stock equivalents being anti-dilutive. See Note 7 for more details.

Recent Accounting Pronouncements

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. The amendments in Part I of this ASU change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic earnings per share. For public business entities, the amendments are

effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The amendments should be applied retrospectively to outstanding financial instruments with down round features by means of either a cumulative-effect adjustment to the consolidated statement of financial position as of the beginning of the first fiscal year and interim period of adoption or retrospectively to each prior reporting period presented in accordance with the guidance on accounting changes. We are currently in the process of evaluating the effect this standard will have on our derivative liabilities and the impact on our condensed consolidated financial position and results of operation.

Table of Contents

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments. This ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The issues addressed in this ASU that will affect us is classifying debt prepayments or debt extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual and interim periods beginning after December 15, 2017, and interim periods within that reporting period and is to be applied using a retrospective transition method to each period presented. Early adoption is permitted. We have elected to early adopt ASU 2016-15 as of January 1, 2017 and, as a result, the prepayment penalty of \$127,247 in connection with the extinguishment of the 2016 Notes (see Note 5) in March 2017 is classified as a financing cash outflow in the accompanying condensed consolidated statement of cash flows for the six months ended June 30, 2017. The adoption of this ASU did not have a material impact on our condensed consolidated financial position, results of operations and related disclosures and had no other impact to the accompanying condensed consolidated statement of cash flows for the six months ended June 30, 2017 and 2016.

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Compensation - Stock Compensation. The ASU involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities and classification on the statement of cash flows. Certain of these changes are required to be applied retrospectively, while other changes are required to be applied prospectively. ASU 2016-09 is effective for public business entities for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. As a result of the adoption of this ASU as of January 1, 2017, we have made an entity-wide accounting policy election to account for forfeitures when they occur. There is no cumulative-effect adjustment as a result of the adoption of this ASU as our estimated forfeiture rate prior to adoption of this ASU was 0%. The adoption of this ASU did not have a material impact on our condensed consolidated financial statements and related disclosures.

NOTE 2 – LICENSE AGREEMENTS

CRI In-License Agreement

On April 19, 2013, the Company and Centric Research Institute (“CRI”) entered into an asset purchase agreement (the “CRI Asset Purchase Agreement”) pursuant to which we acquired:

All of CRI’s rights in past, present and future Sensum+® product formulations and presentations, and

An exclusive, perpetual license to commercialize Sensum+® products in all territories except for the United States.

On June 9, 2016, the Company and CRI amended the CRI Asset Purchase Agreement (“Amended CRI Asset Purchase Agreement”) to provide us commercialization rights for Sensum+® in the U.S. through our Beyond Human® marketing platform through December 31, 2016. On January 1, 2017, the Company and CRI agreed to extend the term of the Amended CRI Asset Purchase Agreement to December 31, 2017. In connection with the extension, we issued restricted shares of common stock totaling 225,000 to CRI as a prepayment of royalties due on net profit of Sensum+® in the U.S. in 2017. The royalty prepayment amount is \$44,662 as the number of shares of common stock issued was based on the closing price of our common stock on December 30, 2016. If CRI does not earn royalties

larger than the prepaid amount of \$44,662 in 2017, the term of the Amended CRI Asset Purchase Agreement is automatically extended one additional year to December 31, 2018.

The CRI Asset Purchase Agreement also requires us to pay to CRI up to \$7.0 million in cash milestone payments based on first achievement of annual Ex-U.S. net sales targets plus a royalty based on annual Ex-U.S. net sales. The obligation for these payments expires on April 19, 2023 or the expiration of the last of CRI's patent claims covering the product or its use outside the U.S., whichever is sooner. No sales milestone obligations have been met and no royalties are owed to CRI under this agreement during the three and six months ended June 30, 2017 and 2016.

Table of Contents

In consideration for the Amended CRI Asset Purchase Agreement, we are required to pay CRI a percentage of the monthly net profit, as defined in the agreement, from our sales of Sensum+® in the U.S. through our Beyond Human® marketing platform. During the three and six months ended June 30, 2017 and 2016, no amounts have been earned by CRI under the Amended CRI Asset Purchase Agreement.

Densmore Pharmaceutical International Agreement

On April 24, 2017, we entered into an exclusive ten-year license agreement with Densmore Pharmaceutical International, a Monaco company (“Densmore”), under which we granted to Densmore an exclusive license to market and sell our topical treatment for Female Sexual Interest/Arousal Disorder (“FSI/AD”) Zestra® in France and Belgium. Under the agreement, we received a non-refundable upfront payment of \$7,500 which was recognized as revenue in the accompanying condensed consolidated statement of operations for the three and six months ended June 30, 2017. We believe the amount of the upfront payment received is reasonable compared to the amounts to be received upon obtainment of future minimum order quantities. Densmore is obligated to order certain minimum annual quantities of Zestra® at a pre-negotiated transfer price per unit during the term of the agreement. During the three and six months ended June 30, 2017, we did not recognize any revenue for the sale of products related to this agreement but we did receive a deposit of \$46,769 for Densmore’s initial order of approximately \$95,000 which is included in deferred revenue and customer deposits in the accompanying condensed consolidated balance sheet as of June 30, 2017.

In July 2017, we entered into an amendment to the agreement with Densmore to expand the product territory to Singapore and Vietnam.

Luminarie Pty Ltd. Agreement

On May 16, 2017, we entered into an exclusive ten-year license agreement with Luminarie Pty Ltd., a Australia company (“Luminarie”), under which we granted to Luminarie an exclusive license to market and sell our topical treatment for FSI/AD Zestra® and Zestra Glide® in Australia, New Zealand and the Philippines. Luminarie received approval for Zestra® as a Class I Medical Device in Australia in July 2017. Luminarie is obligated to order certain minimum annual quantities of Zestra® and Zestra Glide® at a pre-negotiated transfer price per unit during the term of the agreement. During the three and six months ended June 30, 2017, we did not recognize any revenue for the sale of products related to this agreement.

J&H Co. LTD Agreement

On November 9, 2016, we entered into an exclusive ten-year license agreement with J&H Co. LTD, a South Korea company (“J&H”), under which we granted to J&H an exclusive license to market and sell our topical treatment for Female Sexual Interest/Arousal Disorder (“FSI/AD”) Zestra® and Zestra Glide® in South Korea. Under the agreement, J&H is obligated to order minimum annual quantities of Zestra® and Zestra Glide® totaling \$2.0 million at a pre-negotiated transfer price per unit. The minimum annual order quantities by J&H are to be made over a 12-month period following the approval of the product by local authorities and beginning upon the completion of the first shipment of product. Our partner recently received the approval to import the product and placed its first order in March 2017. During the three and six months ended June 30, 2017, we recognized \$0 and \$60,000 in revenue for the sale of products related to this agreement.

Sothema Laboratories Agreement

On September 23, 2014, we entered into an exclusive license agreement with Sothema Laboratories, SARL, a Moroccan publicly traded company (“Sothema”), under which we granted to Sothema an exclusive license to market

and sell Zestra® (based on the latest Canadian approval of the indication) and Zestra Glide® in several Middle Eastern and African countries (collectively the “Territory”).

Under the agreement, we received an upfront payment of \$200,000 and are eligible to receive additional consideration upon and subject to the achievement of sales milestones based on cumulative supplied units of the licensed products in the Territory, plus a pre-negotiated transfer price per unit. We believe the amount of the upfront payment received is reasonable compared to the amounts to be received upon obtainment of future sales-based milestones.

As the sales-based milestones do not meet the definition of a milestone under ASC 605-28, we will recognize the revenue from the milestone payments when the cumulative supplied units’ volume is met. During the three and six months ended June 30, 2017 and 2016, we recognized \$0 and \$2,563 and \$0 and \$11,563, respectively, in net revenue for the sales of products related to this agreement, and no revenue was recognized for the sales-based milestones of the agreement.

Table of Contents

Orimed Pharma Agreement

On September 18, 2014, we entered into a twenty-year exclusive license agreement with Orimed Pharma (“Orimed”), an affiliate of JAMP Pharma, under which we granted to Orimed an exclusive license to market and sell in Canada Zestra®, Zestra Glide®, our topical treatment for premature ejaculation EjectDelay® and our product Sensum+® to increase penile sensitivity.

Under the agreement, we received an upfront payment of \$100,000 and are eligible to receive additional consideration upon and subject to the achievement of sales milestones based on cumulative gross sales in Canada by Orimed plus double-digit tiered royalties based on Orimed’s cumulative net sales in Canada. We believe the amount of the upfront payment received is reasonable compared to the amounts to be received upon obtainment of future sales-based milestones.

As the sales-based milestones do not meet the definition of a milestone under ASC 605-28, we will recognize the revenue from the milestone payments when the cumulative gross sales volume is met. We will recognize the revenue from the royalty payments on a quarterly basis when the cumulative net sales have been met. During the three and six months ended June 30, 2017 and 2016, under this agreement we recognized \$20,942 and \$7,483 and \$20,942 and \$63,586, respectively, in net revenue for the sales of products and no revenue was recognized for the sales-based milestones.

NOTE 3 – BUSINESS AND ASSET ACQUISITIONS

Acquisition of Assets of Beyond Human in 2016

On February 8, 2016, we entered into an Asset Purchase Agreement (“APA”), pursuant to which we agreed to purchase substantially all of the assets of Beyond Human® (the “Acquisition”) for a total cash payment of up to \$662,500 (the “Purchase Price”). The Purchase Price was payable in the following manner: (1) \$300,000 in cash at the closing of the Acquisition (the “Initial Payment”), (2) \$100,000 in cash four months from the closing upon the occurrence of certain milestones as described in the APA, (3) \$100,000 in cash eight months from the closing upon the occurrence of certain milestones as described in the APA, and (4) \$130,000 in cash in twelve months from the closing upon the occurrence of certain milestones as described in the APA. An additional \$32,500 in cash is due if certain milestones occur twelve months from closing. The transaction closed on March 1, 2016. On September 6, 2016, the Company and the sellers entered into an agreement in which we agreed to pay the sellers \$150,000 to settle the contingent consideration payments totaling up to \$362,500 under the APA. The settlement agreement was not contemplated at the time of the acquisition and the fair value of the contingent consideration on the date of settlement was \$330,000. As a result, we recorded a non-cash gain on contingent consideration of \$180,000 during the year ended December 31, 2016.

Table of Contents

Acquisition of Novalere in 2015

On February 5, 2015 (the “Closing Date”), Innovus, Innovus Pharma Acquisition Corporation, a Delaware corporation and a wholly-owned subsidiary of Innovus (“Merger Subsidiary I”), Innovus Pharma Acquisition Corporation II, a Delaware corporation and a wholly-owned subsidiary of Innovus (“Merger Subsidiary II”), Novalere FP, Inc., a Delaware corporation (“Novalere FP”) and Novalere Holdings, LLC, a Delaware limited liability company (“Novalere Holdings”), as representative of the shareholders of Novalere (the “Novalere Stockholders”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Merger Subsidiary I merged into Novalere and then Novalere merged with and into Merger Subsidiary II (the “Merger”), with Merger Subsidiary II surviving as a wholly-owned subsidiary of Innovus. Pursuant to the articles of merger effectuating the Merger, Merger Subsidiary II changed its name to Novalere, Inc.

With the Merger, we acquired the worldwide rights to market and sell the FlutiCare™ brand (fluticasone propionate nasal spray) and the related third-party manufacturing agreement for the manufacturing of FlutiCare™ (“Acquisition Manufacturer”) from Novalere FP. The OTC Abbreviated New Drug Application (“ANDA”) for fluticasone propionate nasal spray was filed at the end of 2014 by our third-party manufacturer and partner, who is currently selling the prescription version of the drug, with the FDA and the OTC ANDA is still subject to FDA approval. An ANDA is an application for a U.S. generic drug approval for an existing licensed medication or approved drug. A prescription ANDA (“RX ANDA”) is for a generic version of a prescription pharmaceutical and an OTC ANDA is for a generic version of an OTC pharmaceutical.

Due to the delay in approval of the Acquisition Manufacturer’s OTC ANDA by the FDA, in May 2017, we announced a commercial relationship with a different third-party manufacturer (West-Ward Pharmaceuticals International Limited or “WWPIL”) who has an FDA approved OTC ANDA for fluticasone propionate nasal spray under which they have agreed to manufacture our FlutiCare™ OTC product for sale in the U.S. (see Note 9). We currently still anticipate that the OTC ANDA filed in November 2014 by the Acquisition Manufacturer with the FDA may be approved in 2017. As we hold the worldwide rights to market and sell FlutiCare™ under the manufacturing agreement with the Acquisition Manufacturer, we believe the agreement with the Acquisition Manufacturer will still provide us with the opportunity to market and sell FlutiCare™ ex-U.S. and, if the OTC ANDA is approved by the FDA, a second source of supply within the U.S., if ever needed.

The Novalere Stockholders are entitled to receive, if and when earned, earn-out payments (the “Earn-Out Payments”). For every \$5.0 million in Net Revenue (as defined in the Merger Agreement) realized from the sales of FlutiCare™ through the manufacturing agreement with the Acquisition Manufacturer, the Novalere Stockholders will be entitled to receive, on a pro rata basis, \$500,000, subject to cumulative maximum Earn-Out Payments of \$2.5 million. The Novalere Stockholders are only entitled to the Earn-Out Payments from the Acquisition Manufacturer’s OTC ANDA under review by the FDA and have no earn-out rights to the sales of FlutiCare™ supplied by WWPIL under the commercial agreement entered into in May 2017.

During the three and six months ended June 30, 2017, there was an increase (decrease) in the estimated fair value of the remaining 138,859 ANDA consideration shares totaling \$400 and (\$19,707) which is included in fair value adjustment for contingent consideration in the accompanying condensed consolidated statement of operations. The remaining 138,859 ANDA consideration shares not issuable yet will be issued upon FDA approval of the ANDA filed by the Acquisition Manufacturer and the estimated fair value of such remaining shares of \$12,509 is included in contingent consideration in the accompanying condensed consolidated balance sheet at June 30, 2017. There was no change to the estimated fair value of the future earn-out payments of \$1,248,124 during the three and six months ended June 30, 2017 and there was no change to the estimated fair value of the contingent consideration during the three and six months ended June 30, 2016.

Purchase of Semprae Laboratories, Inc. in 2013

On December 24, 2013 (the “Semprae Closing Date”), we, through Merger Sub, obtained 100% of the outstanding shares of Semprae in exchange for the issuance of 3,201,776 shares of our common stock, which shares represented 15% of our total issued and outstanding shares as of the close of business on the Closing Date, whereupon Merger Sub was renamed Semprae Laboratories, Inc. We agreed to pay the former shareholders an annual royalty (“Royalty”) equal to 5% of the net sales from Zestra® and Zestra Glide® and any second generation products derived primarily therefrom (“Target Products”) up until the time that a generic version of such Target Product is introduced worldwide by a third party.

-12-

Table of Contents

The agreement to pay the annual Royalty resulted in the recognition of a contingent consideration, which is recognized at the inception of the transaction, and subsequent changes to estimate of the amounts of contingent consideration to be paid will be recognized as charges or credits in the consolidated statement of operations. The fair value of the contingent consideration is based on preliminary cash flow projections, growth in expected product sales and other assumptions. During the three and six months ended June 30, 2017 and 2016, no amounts have been paid under this arrangement. The fair value of the expected royalties to be paid was decreased by \$99,379 and \$0 and \$106,447 and \$0 during the three and six months ended June 30, 2017 and 2016, respectively, which is included in the fair value adjustment for contingent consideration in the accompanying condensed consolidated statements of operations. The fair value of the contingent consideration was \$299,130 and \$405,577 at June 30, 2017 and December 31, 2016, respectively, based on the new estimated fair value of the consideration.

NOTE 4 – ASSETS AND LIABILITIES

Inventories

Inventories consist of the following:

	June 30,	December 31,
	2017	2016
Raw materials and supplies	\$107,973	\$85,816
Work in process	135,834	48,530
Finished goods	342,648	465,510
Total	\$586,455	\$599,856

Intangible Assets

Amortizable intangible assets consist of the following:

	June 30, 2017			
	Amount	Accumulated Amortization	Net Amount	Useful Lives (years)
Patent & Trademarks	\$417,597	\$(108,005)	\$309,592	7 – 15
Customer Contracts	611,119	(218,984)	392,135	10
Sensum+® License (from CRI)	234,545	(95,736)	138,809	10
Vesele® Trademark	25,287	(8,627)	16,660	8
Beyond Human® Website and Trade Name	222,062	(52,514)	169,548	5 – 10
Novalere Manufacturing Contract	4,681,000	(1,121,490)	3,559,510	10
Other Beyond Human® Intangible Assets	4,730	(2,935)	1,795	1 – 3

Edgar Filing: INNOVUS PHARMACEUTICALS, INC. - Form 10-Q

Total \$6,196,340 \$(1,608,291) \$4,588,049

December 31, 2016

	Amount	Accumulated Amortization	Net Amount	Useful Lives (years)
Patent & Trademarks	\$417,597	\$(91,201)	\$326,396	7 – 15
Customer Contracts	611,119	(188,428)	422,691	10
Sensum+® License (from CRI)	234,545	(84,009)	150,536	10
Vesele® Trademark	25,287	(7,047)	18,240	8
Beyond Human® Website and Trade Name	222,062	(32,821)	189,241	5 – 10
Novalere Manufacturing Contract	4,681,000	(887,440)	3,793,560	10
Other Beyond Human® Intangible Assets	4,730	(2,147)	2,583	1 – 3
Total	\$6,196,340	\$(1,293,093)	\$4,903,247	

-13-

Table of Contents

Amortization expense for the three and six months ended June 30, 2017 and 2016 was \$157,473 and \$178,083 and \$315,198 and \$335,685, respectively. The following table summarizes the approximate expected future amortization expense as of June 30, 2017 for intangible assets:

Remainder of 2017	\$314,000
2018	630,000
2019	629,000
2020	629,000
2021	600,000
2022	592,000
Thereafter	1,194,000
	\$4,588,000

Prepaid Expense and Other Current Assets

Prepaid expense and other current assets consist of the following:

	June 30,	December 31,
	2017	2016
Prepaid insurance	\$16,391	\$69,976
Prepaid inventory	133,937	20,750
Merchant net settlement reserve receivable	-	221,243
Prepaid consulting and other expense	94,283	21,094
Prepaid CRI royalties (see Note 2)	44,662	-
Prepaid consulting and other service stock-based compensation expense (see Note 7)	105,000	530,601
Total	\$394,273	\$863,664

Accounts Payable and Accrued Expense

Accounts payable and accrued expense consist of the following:

	June 30,	December 31,
	2017	2016
Accounts payable	\$989,040	\$647,083
Accrued credit card balances	36,348	31,654
Accrued royalties	115,802	73,675
Sales returns and allowances	50,632	60,853
Accrual for stock to be issued to consultants (see Note 7)	-	360,000
Accrued other	64,729	36,785
Total	\$1,256,551	\$1,210,050

NOTE 5 – NOTES PAYABLE AND DEBENTURES – NON-RELATED PARTIES

Notes Payable

The following table summarizes the outstanding notes payable at June 30, 2017 and December 31, 2016:

	2017	2016
Notes payable:		
February 2016 Note Payable	\$209,040	\$347,998
December 2016 and January 2017 Notes Payable	715,000	550,000
Total notes payable	924,040	897,998
Less: Debt discount	(104,788)	(216,871)
Carrying value	819,252	681,127
Less: Current portion	(819,252)	(626,610)
Notes payable, net of current portion	\$-	\$54,517

The following table summarizes the future minimum payments as of June 30, 2017 for the notes payable:

Remainder of 2017	\$869,005
2018	54,985
	\$924,040

Table of Contents

February 2016 Note Payable

On February 24, 2016, the Company and SBI Investments, LLC, 2014-1 (“SBI”) entered into an agreement in which SBI loaned us gross proceeds of \$550,000 pursuant to a purchase agreement, 20% secured promissory note and security agreement (“February 2016 Note Payable”), all dated February 19, 2016 (collectively, the “Finance Agreements”), to purchase substantially all of the assets of Beyond Human® (see Note 3). Of the \$550,000 gross proceeds, \$300,000 was paid into an escrow account held by a third party bank and was released to Beyond Human® upon closing of the transaction, \$242,500 was provided directly to us for use in building the Beyond Human® business and \$7,500 was provided for attorneys’ fees. The attorneys’ fees were recorded as a discount to the carrying value of the February 2016 Note Payable.

Pursuant to the Finance Agreements, the principal amount of the February 2016 Note Payable is \$550,000 and the interest rate thereon is 20% per annum. We began to pay principal and interest on the February 2016 Note Payable on a monthly basis beginning on March 19, 2016 for a period of 24 months and the monthly mandatory principal and interest payment amount thereunder is \$28,209. The monthly amount shall be paid by us through a deposit account control agreement with a third-party bank in which SBI shall be permitted to take the monthly mandatory payment amount from all revenue received by us from the Beyond Human® assets in the transaction. The maturity date for the February 2016 Note Payable is February 19, 2018.

The February 2016 Note Payable is secured by SBI through a first priority secured interest in all of the Beyond Human® assets acquired by us in the transaction including all revenue received by us from these assets

December 2016 and January 2017 Notes Payable

On December 5, 2016 and January 19, 2017, we entered into a securities purchase agreement with three unrelated third-party investors in which the investors loaned us gross proceeds of \$500,000 in December 2016 and \$150,000 in January 2017 pursuant to a 5% promissory note (“December 2016 & January 2017 Notes Payable”). The notes have an Original Issue Discount (“OID”) of \$65,000 and require payment of \$715,000 in principal upon maturity. The December 2016 & January 2017 Notes Payable bear interest at the rate of 5% per annum and the principal amount and interest are payable at maturity on October 4, 2017 and November 18, 2017 for those received in December 2016 and January 2017, respectively.

In connection with the December 2016 & January 2017 Notes Payable, we issued the investors restricted shares of common stock totaling 1,111,111 in December 2016 and 330,000 in January 2017. The fair value of the restricted shares of common stock issued was based on the market price of our common stock on the date of issuance of the December 2016 & January 2017 Notes Payable. The allocation of the proceeds received to the restricted shares of common stock based on their relative fair value and the OID resulted in us recording a debt discount of \$182,203 in December 2016 and \$44,217 in January 2017. The discount is being amortized to interest expense using the effective interest method over the term of the December 2016 & January 2017 Notes Payable.

Interest Expense

We recognized interest expense on notes payable of \$21,656 and \$77,550 and \$46,713 and \$88,915 for the three and six months ended June 30, 2017 and 2016, respectively. Amortization of the debt discount to interest expense during the three and six months ended June 30, 2017 and 2016 totaled \$88,474 and \$94,902 and \$171,300 and \$95,371, respectively.

Convertible Debentures

2016 Financing

The following table summarizes the outstanding 2016 convertible debentures at June 30, 2017 and December 31, 2016:

	2017	2016
Convertible debentures	\$-	\$1,559,922
Less: Debt discount	-	(845,730)
Carrying value	-	714,192
Less: Current portion	-	(714,192)
Convertible debentures, net of current portion	\$-	\$-

Table of Contents

In the second and third quarter of 2016, we entered into Securities Purchase Agreements with eight accredited investors (the “Investors”), pursuant to which we received aggregate gross proceeds of \$3.0 million (net of OID) pursuant to which we sold:

Nine convertible promissory notes of the Company totaling \$3,303,889 (each a “2016 Note” and collectively the “2016 Notes”) (the 2016 Notes were sold at a 10% OID and we received an aggregate total of \$2,657,500 in funds thereunder after debt issuance costs of \$342,500). The 2016 Notes and accrued interest were convertible into shares of our common stock at a conversion price of \$0.25 per share, with certain adjustment provisions. The maturity date of the 2016 Notes issued on June 30, 2016 and July 15, 2016 was July 30, 2017 and the maturity date of the 2016 Notes issued on July 25, 2016 was August 25, 2017. The 2016 Notes bore interest on the unpaid principal amount at the rate of 5% per annum from the date of issuance until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. We had the ability to prepay the 2016 Notes at any time on the terms set forth in the 2016 Notes at the rate of 110% of the then outstanding balance of the 2016 Notes.

The fair value of the restricted shares of common stock issued to Investors in 2016 was based on the market price of our common stock on the date of issuance of the 2016 Notes. The allocation of the proceeds to the warrants and restricted shares of common stock based on their relative fair values resulted in us recording a debt discount. We also determined that the embedded conversion features in the 2016 Notes were a derivative instrument which was required to be bifurcated from the debt host contract and recorded at fair value as a derivative liability. The fair value of the embedded conversion features was determined using a Path-Dependent Monte Carlo Simulation Model (see Note 8 for assumptions used to calculate fair value). The initial fair value of the embedded conversion features was recorded as a debt discount with the amount in excess of the proceeds allocated to the debt, after the allocation of debt proceeds to the debt issuance costs, being immediately expensed and recorded as interest expense in 2016.

During the six months ended June 30, 2017, certain of the 2016 Notes holders elected to convert principal and interest outstanding of \$350,610 into 1,402,440 shares of common stock at a conversion price of \$0.25 per share (see Note 7). As a result of the conversion of the principal and interest balance into shares of common stock, the fair value of the embedded conversion feature derivative liabilities of \$203,630 on the date of conversion was reclassified to additional paid-in capital (see Note 8) and the amortization of the debt discount was accelerated for the amount converted and recorded to interest expense during the six months ended June 30, 2017.

As a result of the completion of a public equity offering in March 2017 (see Note 7), we were required to prepay the outstanding principal and accrued interest balance of the 2016 Notes with the cash proceeds received from such offering. The outstanding principal and accrued interest balance of \$1,272,469 was repaid in March 2017, as well as, a 10% prepayment penalty of \$127,247. Due to the acceleration of repayment of the 2016 Notes as a result of the public equity offering, the transaction was recorded as a debt extinguishment and the 10% prepayment penalty of \$127,247 and the remaining unamortized debt discount as of the date of repayment of \$415,682 were recorded as a loss on debt extinguishment in the accompanying condensed consolidated statement of operations for the six months ended June 30, 2017. The repayment of the outstanding principal and accrued interest balance of the 2016 Notes resulted in the extinguishment of the embedded conversion feature derivative liability and thus the fair value as of the date of repayment of \$238,101 was recorded as a reduction to the loss on debt extinguishment in the accompanying condensed consolidated statement of operations for the six months ended June 30, 2017.

Interest Expense

We recognized interest expense on the 2016 Notes for the six months ended June 30, 2017 of \$19,544. The debt discount recorded for the 2016 Notes were being amortized as interest expense over the term of the 2016 Notes using the effective interest method. Total amortization of the debt discount on the 2016 Notes to interest expense for the six

months ended June 30, 2017 was \$430,048.

-16-

Table of Contents

NOTE 6 – RELATED PARTY TRANSACTIONS

Accrued Compensation – Related Party

Accrued compensation includes accruals for employee wages, vacation pay and target-based bonuses. The components of accrued compensation as of June 30, 2017 and December 31, 2016 are as follows:

	June 30, 2017	December 31, 2016
Wages	\$1,431,686	\$1,455,886
Vacation	302,663	261,325
Bonus	693,431	449,038
Payroll taxes on the above	148,759	133,344
Total	2,576,539	2,299,593
Classified as long-term	(1,036,315)	(1,531,904)
Accrued compensation	\$1,540,224	\$767,689

Accrued employee wages at June 30, 2017 and December 31, 2016 are entirely related to wages owed to our President and Chief Executive Officer. Under the terms of his employment agreement, wages are to be accrued but no payment made for so long as payment of such salary would jeopardize our ability to continue as a going concern. The President and Chief Executive Officer started to receive payment of salary in July 2016. In the second quarter of 2017, it was determined by our Board of Directors that deferred salary of \$463,167 would be paid to our current President and Chief Executive Officer to assist in paying the statutory personal tax withholding on the shares of common stock he received in 2016 for his vested restricted stock units. As a result, the deferred salary amount and related employer taxes totaling \$495,589 has been classified as current. The payment of such deferred salary would not jeopardize our ability to continue as a going concern, and the payment has not been made as of the date of filing of this quarterly report. Our President and Chief Executive Officer has agreed to not receive payment on the remaining accrued wages and related payroll tax amounts within the next 12 months and thus the remaining balance is classified as a long-term liability. In April 2017, our Board of Directors approved for payment the accrued fiscal year 2016 bonus of \$33,442 to our former Executive Vice President and Chief Financial Officer in accordance with his employment agreement and the bonus amount was paid upon his departure. The fiscal year 2016 bonus for our President and Chief Executive Officer has not yet been approved by our Board of Directors but is included in accrued compensation in the accompanying condensed consolidated balance sheets as of June 30, 2017 and December 31, 2016.

Table of Contents

NOTE 7 – STOCKHOLDERS’ EQUITY

Issuances of Common Stock

Public Equity Offering

On March 21, 2017, we completed a sale of common stock and warrants under a registered public offering. The gross proceeds to us from the offering were \$3,850,000, before underwriting discounts and commissions and other offering expenses (\$3,307,773 after underwriting discounts, commissions and expenses).

The public offering price per share of common stock sold was \$0.15. Each investor who purchased a share of common stock in the offering received a five-year warrant to purchase one share of common stock at an exercise price of \$0.15 per share (“Series A Warrants”) and a one-year warrant to purchase one share of common stock at an exercise price of \$0.15 per share (“Series B Warrants”). Under the terms of the offering, we issued 25,666,669 shares of common stock, Series A Warrants to purchase up to an aggregate of 25,666,669 shares of common stock and Series B Warrants to purchase up to an aggregate of 25,666,669 shares of common stock. The Series A Warrants and Series B Warrants are exercisable immediately. We allocated the net proceeds received of \$3,307,773 to the shares of common stock, Series A Warrants and Series B Warrants sold in the offering based on their relative fair values. The fair value of the Series A Warrants and Series B Warrants was determined using Black-Scholes. Based on their relative fair values, we allocated net of proceeds of \$1,593,233 to the shares of common stock, \$1,075,995 to the Series A Warrants and \$638,545 to the Series B Warrants.

In connection with this offering, we issued to H.C. Wainwright & Co. (“HCW”), the underwriter in the offering, a warrant to purchase up to 1,283,333 shares of common stock and HCW received total cash consideration, including the reimbursement of public offering-related expenses, of \$443,000. If such warrant is exercised, each share of common stock may be purchased at \$0.1875 per share (125% of the price of the common stock sold in the offering), commencing on March 21, 2017 and expiring March 21, 2022. The fair value of the warrants issued to HCW totaled \$129,755 and was determined using Black-Scholes. The fair value of the warrants was recorded as an offering cost but has no net impact to additional paid-in capital in stockholders’ equity in the accompanying condensed consolidated balance sheet.

In connection with this offering, the Company incurred \$99,227 in other offering costs that have been offset against the proceeds from this offering.

Other Stock Issuances and Related Stock-Based Compensation

On August 23, 2016, we entered into a consulting agreement with a third party pursuant to which we agreed to issue 1,600,000 restricted shares of common stock, payable in four equal installments, in exchange for services to be rendered over the agreement which ends on August 23, 2017. The shares were considered fully-vested and non-refundable at the execution of the agreement. In 2016, we issued 800,000 shares of common stock and during the six months ended June 30, 2017, we issued a total of 800,000 shares of common stock under the agreement. The fair value of the shares issued during 2017 of \$360,000 was based on the market price of our common stock on the date of agreement. There are no more shares of common stock to be issued under this service agreement as of June 30, 2017. During the three and six months ended June 30, 2017, we recognized \$180,000 and \$360,000, respectively, in general and administrative expense in the accompanying condensed consolidated statements of operations and the remaining unamortized expense of \$105,000 is included in prepaid expense and other current assets in the accompanying condensed consolidated balance sheet at June 30, 2017.

On September 1, 2016, we entered into a service agreement with a third party pursuant to which we agreed to issue, over the term of the agreement, 2,000,000 shares of common stock in exchange for services to be rendered. During the six months ended June 30, 2017, we issued 670,000 shares under the agreement related to services provided and recognized the fair value of the shares issued of \$123,615 in general and administrative expense in the accompanying condensed consolidated statement of operations. The 670,000 shares of common stock vested on the date of issuance and the fair value of the shares of common stock was based on the market price of our common stock on the date of vesting. There are no more shares of common stock to be issued under this service agreement as of June 30, 2017.

Table of Contents

On November 17, 2016, we entered into a service agreement with a third party and in connection with the agreement issued 275,000 fully-vested shares for services to be provided over the term of the service agreement through May 17, 2017. The fair value of the shares issued of \$69,575 was based on the market price of our common stock on the date of vesting. During the three and six months ended June 30, 2017, we recognized \$17,394 and \$52,181, respectively, in general and administrative expense in the accompanying condensed consolidated statements of operations.

On December 16, 2016, we amended a consulting agreement with a third party to extend the term of the agreement to June 16, 2017 and in connection with the amendment issued 80,000 fully-vested shares for services to be provided over the remaining term of the amended agreement. The fair value of the shares issued of \$14,640 was based on the market price of our common stock on the date of vesting. On January 19, 2017, we further amended the agreement to expand the scope of service performed by the consultant and as a result issued an additional 78,947 shares of fully vested common stock for services to be provided through June 16, 2017. The fair value of the shares issued of \$15,000 was based on the market price of our common stock on the date of vesting. During the three and six months ended June 30, 2017, we recognized \$13,600 and \$28,420, respectively, in general and administrative expense in the accompanying condensed consolidated statements of operations.

In January 2017 and April 2017, we issued a total of 28,425 shares of common stock for services and recorded an expense of \$2,000 and \$4,000 for the three and six months ended June 30, 2017, respectively, which is included in general and administrative expense in the accompanying condensed consolidated statements of operations. The 28,425 shares of common stock vested on the date of issuance and the fair value of the shares of common stock was based on the market price of our common stock on the date of vesting.

In January 2017, we issued 225,000 shares of common stock to CRI pursuant to the Amended CRI Asset Purchase Agreement (see Note 2) for the prepayment of future royalties due on net profit of Sensum+® in the U.S. in 2017. The fair value of the restricted shares of common stock of \$44,662 was based on the market price of our common stock on the date of issuance and is included in prepaid expense and other current assets in the accompanying condensed consolidated balance sheet at June 30, 2017.

In January 2017, we issued 330,000 shares of restricted common stock to a note holder in connection with their note payable. The relative fair value of the shares of restricted common stock issued was determined to be \$44,217 and was recorded as a debt discount (see Note 5).

In March 2017, certain 2016 Notes holders elected to convert \$350,610 in principal and interest into 1,402,440 shares of common stock (see Note 5). Upon conversion, the fair value of the embedded conversion feature derivative liability on the date of conversion was reclassified to additional paid-in capital (see Note 8).

In March 2017, we issued shares of common stock totaling 40,000 upon the exercise of stock options for total cash proceeds of \$2,894.

In June 2017, we issued 92,000 shares of common stock in exchange for vested restricted stock units.

2013 Equity Incentive Plan

We have issued common stock, restricted stock units and stock option awards to employees, non-executive directors and outside consultants under the 2013 Equity Incentive Plan (“2013 Plan”), which was approved by our Board of Directors in February of 2013. The 2013 Plan allows for the issuance of up to 10,000,000 shares of our common stock to be issued in the form of stock options, stock awards, stock unit awards, stock appreciation rights, performance shares and other share-based awards. As of June 30, 2017, 31,000 shares were available under the 2013 Plan.

Table of Contents

2014 Equity Incentive Plan

We have issued common stock, restricted stock units and stock options to employees, non-executive directors and outside consultants under the 2014 Equity Incentive Plan (“2014 Plan”), which was approved by our Board of Directors in November 2014. The 2014 Plan allows for the issuance of up to 20,000,000 shares of our common stock to be issued in the form of stock options, stock awards, stock unit awards, stock appreciation rights, performance shares and other share-based awards. As of June 30, 2017, 58,367 shares were available under the 2014 Plan.

2016 Equity Incentive Plan

On March 21, 2016, our Board of Directors approved the adoption of the 2016 Equity Incentive Plan and on October 20, 2016 adopted the Amended and Restated 2016 Equity Incentive Plan (“2016 Plan”). The 2016 Plan was then approved by our stockholders in November 2016. The 2016 Plan allows for the issuance of up to 20,000,000 shares of our common stock to be issued in the form of stock options, stock awards, stock unit awards, stock appreciation rights, performance shares and other share-based awards. The 2016 Plan includes an evergreen provision in which the number of shares of common stock authorized for issuance and available for future grants under the 2016 Plan will be increased each January 1 after the effective date of the 2016 Plan by a number of shares of common stock equal to the lesser of: (a) 4% of the number of shares of common stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, or (b) a number of shares of common stock set by our Board of Directors. In March 2017, our Board of Directors approved an increase of 5,663,199 shares of common stock to the shares authorized under the 2016 Plan in accordance with the evergreen provision in the 2016 Plan. As of June 30, 2017, 21,291,727 shares were available under the 2016 Plan.

Stock Options

For the six months ended June 30, 2017 and 2016, the following weighted average assumptions were utilized for the calculation of the fair value of the stock options granted during the period using Black-Scholes:

	2017	2016
Expected life (in years)	8.6	10.0
Expected volatility	217.0%	227.9%
Average risk-free interest rate	2.28%	1.77%
Dividend yield	0%	0%
Grant date fair value	\$0.19	\$0.16

Table of Contents

The dividend yield of zero is based on the fact that we have never paid cash dividends and has no present intention to pay cash dividends. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the stock options. Expected life in years is based on the “simplified” method as permitted by ASC Topic 718. We believe that all stock options issued under its stock option plans meet the criteria of “plain vanilla” stock options. We use a term equal to the term of the stock options for all non-employee stock options. The risk-free interest rate is based on average rates for treasury notes as published by the Federal Reserve in which the term of the rates correspond to the expected term of the stock options.

The following table summarizes the number of stock options outstanding and the weighted average exercise price:

	Options	Weighted average exercise price	Weighted remaining contractual life (years)	Aggregate intrinsic value
Outstanding at December 31, 2016	237,500	\$0.22	8.6	\$14,293
Granted	28,000	0.19	-	-
Exercised	(40,000)	0.07	-	-
Cancelled	(40,000)	0.24	-	-
Forfeited	-	-	-	-
Outstanding at June 30, 2017	185,500	\$0.24	8.2	\$2,466
Vested at June 30, 2017	185,500	\$0.24	8.2	\$2,466

The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding stock options and the quoted price of our common stock at June 30, 2017. During the three and six months ended June 30, 2017 and 2016, the Company recognized stock-based compensation from stock options of \$1,028 and \$5,406 and \$4,000 and \$9,500, respectively. The intrinsic value of the stock options exercised during the six months ended June 30, 2017 on the date of exercise was \$5,306.

Restricted Stock Units

The following table summarizes the restricted stock unit activity for the six months ended June 30, 2017:

	Restricted Stock Units
Outstanding at December 31, 2016	12,874,848
Granted	2,670,547
Exchanged	(92,000)
Cancelled	(2,500,000)
Outstanding at June 30, 2017	12,953,395
Vested at June 30, 2017	9,203,395

The vested restricted stock units at June 30, 2017 have not settled and are not showing as issued and outstanding shares of ours but are considered outstanding for earnings per share calculations. Settlement of these vested restricted stock units will occur on the earliest of (i) the date of termination of service of the employee or consultant, (ii) change of control of us, or (iii) 10 years from date of issuance. Settlement of vested restricted stock units may be made in the form of (i) cash, (ii) shares, or (iii) any combination of both, as determined by the board of directors and is subject to certain criteria having been fulfilled by the recipient.

We calculate the fair value of the restricted stock units based upon the quoted market value of the common stock at the date of grant. The grant date fair value of restricted stock units issued during the six months ended June 30, 2017 was \$491,500. For the three and six months ended June 30, 2017 and 2016, we recognized \$(52,115) and \$168,679 and \$107,885 and \$627,018, respectively, of stock-based compensation expense for the vested units. The credit for the three months ended June 30, 2017 was a result of the reversal of the expense previously recognized on the RSUs granted to our former Chief Financial Officer that were cancelled prior to their initial vesting date upon his departure in April 2017. As of June 30, 2017, compensation expense related to unvested shares not yet recognized in the condensed consolidated statement of operations was approximately \$655,000 and will be recognized over a remaining weighted-average term of 2.4 years.

Table of Contents

Warrants

During the year ended December 31, 2014, we issued warrants in connection with notes payable (which were repaid in 2013). The remaining warrants of 135,816 have an exercise price of \$0.10 and expire December 6, 2018.

In January 2015, we issued 250,000 warrants with an exercise price of \$0.30 per share to a former executive in connection with the January 2015 debenture. The warrants expire on January 21, 2020. The warrants contain anti-dilution protection, including protection upon dilutive issuances. In connection with the convertible debentures issued in 2015, the exercise price of these warrants was reduced to \$0.0896 per share and an additional 586,705 warrants were issued per the anti-dilution protection afforded in the warrant agreement during the year ended December 31, 2015.

In connection with the convertible debentures in 2015, we issued warrants with an exercise price of \$0.30 per share and expire in 2020 to investors and placement agents. Warrants to purchase 774,533 shares of common stock remain outstanding as of June 30, 2017.

In connection with the 2016 Notes, we issued warrants to the Investors and placement agents with an exercise price of \$0.40 per share and expire in 2021. Warrants to purchase 4,220,000 shares of common stock remain outstanding as of June 30, 2017.

In connection with the public equity offering in March 2017, we issued Series A Warrants to purchase 25,666,669 shares of common stock at \$0.15 per share and Series B Warrants to purchase 25,666,669 shares of common stock at \$0.15 per share. The Series A Warrants expire in 2022 and the Series B Warrants expire in 2018. We also issued warrants to purchase 1,283,333 shares of common stock to our placement agent with an exercise price of \$0.1875 per share and expire in 2022.

For the six months ended June 30, 2017, the following weighted average assumptions were utilized for the calculation of the fair value of the warrants issued during the period using Black-Scholes:

	2017
Expected life (in years)	3.1
Expected volatility	203.3%
Average risk-free interest rate	1.49%
Dividend yield	0%

At June 30, 2017, there are 58,583,725 fully vested warrants outstanding. The weighted average exercise price of outstanding warrants at June 30, 2017 is \$0.17 per share, the weighted average remaining contractual term is 2.9 years and the aggregate intrinsic value of the outstanding warrants is \$20,621.

Net Loss per Share

Restricted stock units that are vested but the issuance and delivery of the shares are deferred until the employee or director resigns are included in the basic and diluted net loss per share calculations.

The weighted average shares of common stock outstanding used in the basic and diluted net loss per share calculation for the three and six months ended June 30, 2017 and 2016 was 150,713,121 and 138,587,767 and 77,455,497 and

62,335,408, respectively.

The weighted average restricted stock units vested but issuance of the common stock is deferred until there is a change in control, a specified date in the agreement or the employee or director resigns used in the basic and diluted net loss per share calculation for the three and six months ended June 30, 2017 and 2016 was 9,284,274 and 9,029,297 and 7,940,349 and 7,935,925, respectively.

The total weighted average shares outstanding used in the basic and diluted net loss per share calculation for the three and six months ended June 30, 2017 and 2016 was 159,997,395 and 147,617,064 and 85,395,846 and 70,271,333, respectively.

-22-

Table of Contents

The following table shows the anti-dilutive shares excluded from the calculation of basic and diluted net loss per common share as of June 30, 2017 and 2016:

	As of June 30,	
	2017	2016
Gross number of shares excluded:		
Restricted stock units – unvested	3,750,000	1,893,753
Stock options	185,500	254,500
Convertible debentures and accrued interest	-	6,600,000
Warrants	58,583,725	5,206,011
Total	62,519,225	13,954,264

The above table does not include the ANDA Consideration Shares related to the Novalere acquisition totaling 138,859 and 12,947,655 at June 30, 2017 and 2016, respectively, as they are considered contingently issuable (see Note 3).

NOTE 8 – DERIVATIVE LIABILITIES

The warrants issued in connection with the January 2015 Non-Convertible Debenture to a former executive are measured at fair value and classified as a liability because these warrants contain anti-dilution protection and therefore, cannot be considered indexed to our own stock which is a requirement for the scope exception as outlined under FASB ASC 815. The estimated fair value of the warrants was determined using the Probability Weighted Black-Scholes Model. The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term and the risk-free interest rate. We will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first. The anti-dilution protection for the warrants survives for the life of the warrants which ends in January 2020.

The derivative liabilities are a Level 3 fair value measure in the fair value hierarchy and the assumptions for the Probability Weighted Black-Scholes Option-Pricing Model for the six months ended June 30, 2017 are represented in the table below:

	June 30, 2017
Expected life (in years)	2.56 – 2.97
Expected volatility	179% – 187%
Average risk-free interest rate	1.44% – 1.50%
Dividend yield	0%

We have determined the embedded conversion features of the 2016 Notes (see Note 5) to be derivative liabilities because the terms of the embedded conversion features contained anti-dilution protection and therefore, could not be considered indexed to our own stock which was a requirement for the scope exception as outlined under FASB ASC 815. The embedded conversion features were to be measured at fair value and classified as a liability with subsequent changes in fair value recorded in earnings at the end of each reporting period. We have determined the fair value of

the derivative liabilities using a Path-Dependent Monte Carlo Simulation Model. The fair value of the derivative liabilities using such model was affected by changes in inputs to that model and was based on the individual characteristics of the embedded conversion features on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate, credit spread, probability of default by us and acquisition of us. During the six months ended June 30, 2017, the 2016 Notes were either converted into shares of common stock or repaid in full. The conversion of the 2016 Notes during the six months ended June 30, 2017 resulted in the fair value of the embedded conversion feature derivative liability on the dates of conversion of \$203,630 to be reclassified to additional paid-in capital (see Note 7). Upon repayment of the remaining 2016 Notes in March 2017 (see Note 5), the fair value of the embedded conversion features on date of repayment of \$238,101 was extinguished and included in loss on debt extinguishment in the accompanying condensed consolidated statement of operations.

Table of Contents

The derivative liabilities are a Level 3 fair value measurement in the fair value hierarchy and a summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for our embedded conversion feature derivative liabilities that are categorized within Level 3 of the fair value hierarchy during the six months ended June 30, 2017 is as follows:

	June 30, 2017
Stock price	\$0.103 – \$0.305
Strike price	\$0.25
Expected life (in years)	0.36 – 0.43
Expected volatility	130% – 168%
Average risk-free interest rate	0.78% – 0.87%
Dividend yield	–

At June 30, 2017, the estimated Level 3 fair value of the warrant derivative liabilities measured on a recurring basis is as follows:

	Fair value	Level 1	Level 2	Level 3	Total
Warrant derivative liabilities	\$90,206	\$-	\$-	\$90,206	\$90,206

The following table presents the activity for the Level 3 embedded conversion feature and warrant derivative liabilities measured at fair value on a recurring basis for the six months ended June 30, 2017:

Fair Value Measurements Using Level 3 Inputs

Warrant derivative liabilities:

Beginning balance December 31, 2016	\$164,070
Change in fair value	(73,864)
Ending balance June 30, 2017	\$90,206

Embedded conversion feature derivative liabilities:

Beginning balance December 31, 2016	\$319,674
Reclassification of fair value of embedded conversion feature derivative liability to additional paid-in capital upon conversions of 2016 Notes	(203,630)
Extinguishment of embedded conversion feature upon repayment of 2016 Notes	(238,101)
Change in fair value	122,057
Ending balance June 30, 2017	\$-

NOTE 9 – COMMITMENTS AND CONTINGENCIES

In May 2017, we entered into a commercial agreement with West-Ward Pharmaceuticals International Limited (“WWPIL”), a wholly-owned subsidiary of Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY). Pursuant to the commercial agreement, WWPIL will provide us with the rights to launch our branded, fluticasone propionate nasal spray USP, 50 mcg per spray (FlutiCare™), under WWPIL’s FDA approved ANDA No. 207957 in the U.S. in the fourth quarter of 2017. The initial term of the commercial agreement is for two years, and upon expiration of the initial term, the agreement will automatically renew for subsequent one-year terms unless either party notifies the other party in writing of its desire not to renew at least 90 days prior to the end of the then current term. The agreement requires us to meet certain minimum product batch purchase requirements in order for the agreement to continue to be in effect.

Table of Contents

NOTE 10 – SUBSEQUENT EVENTS

In July 2017, we issued 44,405 shares of common stock to a consultant for services rendered. The fair value of the common stock issued was \$5,000.

On July 20, 2017, we entered into a service agreement with a third party pursuant to which we agreed to issue, over the term of the agreement through December 31, 2017, 1,200,000 shares of common stock in exchange for services to be rendered. Upon execution of the agreement, we issued 200,000 shares to the third party with a fair value of the shares issued of \$24,200.

In July 2017, we issued shares of common stock totaling 31,500 upon the exercise of stock options for total cash proceeds of \$1,985.

We have evaluated subsequent events through the filing date of this Form 10-Q and determined that no additional subsequent events have occurred that would require recognition in the condensed consolidated financial statements or disclosures in the notes thereto other than as disclosed in the accompanying notes to the condensed consolidated financial statements.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Innovus Pharmaceuticals, Inc., together with its subsidiaries, are collectively referred to as "Innovus", the "Company", "us", "we", or "our". The following information should be read in conjunction with the condensed consolidated financial statements and notes thereto appearing elsewhere in this report. For additional context with which to understand our financial condition and results of operations, see the discussion and analysis included in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission ("SEC") on March 9, 2017, as well as the consolidated financial statements and related notes contained therein.

Forward Looking Statements

Certain statements in this report, including information incorporated by reference, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements reflect current views about future events and financial performance based on certain assumptions. They include opinions, forecasts, intentions, plans, goals, projections, guidance, expectations, beliefs or other statements that are not statements of historical fact. Words such as "may," "should," "could," "would," "expects," "plans," "believes," "anticipates," "intends," "estimates," "approximates," "predicts," or "projects," or the negative or other variation of such words and similar expressions may identify a statement as a forward-looking statement. Any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results and the development of our products, are forward-looking statements.

Although forward-looking statements in this Quarterly Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the heading "Risks Factors" below, as well as those discussed elsewhere in this Quarterly Report on Form 10-Q. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We file reports with the SEC. You can read and copy any materials we file with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain additional information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.

Overview

We are an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. We deliver innovative and uniquely presented and packaged health solutions through our (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our print media, on-line channels, retailers and wholesalers. We are dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. We are actively pursuing opportunities where existing prescription drugs have recently, or are

expected to, change from prescription (or Rx) to OTC. These “Rx-to-OTC switches” require Food and Drug Administration (“FDA”) approval through a process initiated by the New Drug Application (“NDA”) holder.

Table of Contents

Our business model leverages our ability to (a) develop and build our current pipeline of products, and (b) to also acquire outright or in-license commercial products that are supported by scientific and/or clinical evidence, place them through our existing supply chain, retail and on-line (including Amazon®-based business platform) channels to tap new markets and drive demand for such products and to establish physician relationships. We currently have 21 products marketed in the U.S. with six of those being marketed and sold in multiple countries around the world through some of our 15 commercial partners. We currently expect to launch an additional five products in the U.S. in the second half of 2017 and we currently have approvals to launch certain of our already marketed products in 33 additional countries.

Our Strategy

Our corporate strategy focuses on two primary objectives:

1. Developing a diversified product portfolio of exclusive, unique and patented non-prescription OTC and branded ANDA drugs and consumer health products through: (a) the introduction of line extensions and reformulations of either our or third-party currently marketed products; and (b) the acquisition of products or obtaining exclusive licensing rights to market such products; and
2. Building an innovative, U.S. and global sales and marketing model through direct to consumer approaches such as our proprietary Beyond Human® sales and marketing platform, the addition of new online platforms such as Amazon® and commercial partnerships with established international complimentary partners that: (a) generates revenue, and (b) requires a lower cost structure compared to traditional pharmaceutical companies thereby increasing our gross margins.

Our Products

We currently generate revenue from 21 products in the U.S. and six in international countries, as follows:

1. Vesele® for promoting sexual health (U.S. and U.K.);
2. Zestra® for female arousal (U.S., U.K., Denmark, Canada, Morocco, the UAE and South Korea);
3. Zestra Glide® (U.S, Canada and the MENA countries);
4. UriVarx™ for bladder health;
5. Sensum+® to alleviate reduced penile sensitivity (U.S., U.K. and Morocco);
6. ProstaGorx™ for prostate health;
7. AllerVarx™ for the management of allergy symptoms;
8. Apez™ for arthritis related pain;
9. ArthriVarx™ for joint health;

- 10
EjectDelay® indicated for the treatment of premature ejaculation (U.S. and Canada);
11.
RecalMax™ for brain health;
12.
Androferti® (U.S. and Canada) for the support of overall male reproductive health and sperm quality;
13.
Beyond Human® Testosterone Booster;
14.
Beyond Human® Ketones;
15.
Beyond Human® Krill Oil;
16.
Beyond Human® Omega 3 Fish Oil;
17.
Beyond Human® Vision Formula;
18.
Beyond Human® Blood Sugar;
19.
Beyond Human® Colon Cleanse;
20.
Beyond Human® Green Coffee Extract; and
21.
Beyond Human® Growth Agent.

Table of Contents

In addition, we currently expect to launch in the U.S. the following products in the second half of 2017, subject to the applicable regulatory approvals, if required:

1. FlutiCare™ for allergic rhinitis;
2. Xyralid™ for the relief of the pain and symptoms caused by hemorrhoids;
3. PEVarx™ for extension of sexual intercourse time;
4. AndroVit™ for men's health; and
5. Urocis™ XR for urinary tract infections.

Sales and Marketing Strategy U.S. and Internationally

Our sales and marketing strategy is based on (a) the use of direct to consumer advertisements in print and online media through our proprietary Beyond Human® sales and marketing infrastructure acquired in March 2016, (b) working with direct commercial channel partners in the U.S. and also directly marketing the products ourselves to physicians, urologists, gynecologists and therapists and to other healthcare providers, and (c) working with exclusive commercial partners outside of the U.S. that would be responsible for sales and marketing in those territories. We have now fully integrated most of our existing line of products such as Vesele®, Sensum+®, UriVarx™, Zestra®, RecalMax™, ProstaGorx™ and AllerVarx™ into the Beyond Human® sales and marketing platform. We plan to integrate Apeaz™, ArthriVarx™, Xyralid™, AndroVit™, Urocis™ XR; and FlutiCare™ upon their expected commercial launches in 2017. We also market and distribute our products in the U.S. through retailers, wholesalers and other online channels. Our strategy outside the U.S. is to partner with companies who can effectively market and sell our products in their countries through their direct marketing and sales teams. The strategy of using our partners to commercialize our products is designed to limit our expenses and fix our cost structure, enabling us to increase our reach while minimizing our incremental spending.

Our current OTC monograph, Rx-to-OTC ANDA switch drugs and consumer care products marketing strategy is to focus on four main U.S. markets: (1) sexual health (male sexual dysfunction and health); (2) urology (bladder and prostate health); (3) respiratory disease; and (4) migraines and brain health. We will focus our current efforts on these four markets and will seek to develop, acquire or license products that we can sell through our sales channels in these fields.

In May 2017, we entered into a commercial agreement with West-Ward Pharmaceuticals International Limited (“WWPIL”). Pursuant to the commercial agreement, WWPIL will provide us with the rights to launch our branded, fluticasone propionate nasal spray USP, 50 mcg per spray (FlutiCare™), under WWPIL’s FDA approved ANDA No. 207957 in the U.S. in the fourth quarter of 2017. Upon launch of FlutiCare™, it will be the third national branded OTC fluticasone propionate nasal spray in the allergic rhinitis market. Our current sales and marketing strategy for the launch of the product consists of the following:

1. Finalizing agreements with wholesalers, retail stores in which we are a vendor of record and independent pharmacies;
2. Provide sampling to the top prescribers of fluticasone propionate;

3. Implement direct sampling and coupon programs to consumers to continue to build brand awareness;
4. Launch under our Beyond Human® sales and marketing platform through print and online media; and
5. Launch through our online platforms including our website, email subscriber lists and Amazon®.

Table of Contents

Results of Operations for the Three and Six Months Ended June 30, 2017 Compared with the Three and Six Months Ended June 30, 2016

	Three Months Ended June 30, 2017	Three Months Ended June 30, 2016	\$ Change	% Change
NET REVENUE:				
Product sales, net	\$2,031,157	\$1,019,520	\$1,011,637	99.2%
License revenue	7,500	-	7,500	100.0%
Net revenue	2,038,657	1,019,520	1,019,137	100.0%
OPERATING EXPENSE:				
Cost of product sales	408,579	262,934	145,645	55.4%
Research and development	15,063	3,892	11,171	287.0%
Sales and marketing	1,555,736	249,515	1,306,221	523.5%
General and administrative	1,182,235	945,572	236,663	25.0%
Total operating expense	3,161,613	1,461,913	1,699,700	116.3%
LOSS FROM OPERATIONS	(1,122,956)	(442,393)	(680,563)	153.8%
OTHER INCOME (EXPENSE):				
Interest expense	(110,130)	(1,860,399)	1,750,269	(94.1)%
Loss on extinguishment of debt	-	-	-	-%
Other income (expense), net	(206)	111	(317)	(285.6)%
Fair value adjustment for contingent consideration	98,979	(16,750)	115,729	(690.9)%
Change in fair value of derivative liabilities	3,463	(2,040,909)	2,044,372	(100.2)%
Total other expense, net	(7,894)	(3,917,947)	3,910,053	(99.8)%
LOSS BEFORE PROVISION FOR INCOME TAXES	(1,130,850)	(4,360,340)	3,229,490	(74.1)%
Provision for income taxes	3,200	-	3,200	100.0%
NET LOSS	\$(1,134,050)	\$(4,360,340)	(3,226,290)	(74.0)%

	Six Months Ended June 30, 2017	Six Months Ended June 30, 2016	\$ Change	% Change
NET REVENUE:				
Product sales, net	\$4,208,447	\$1,243,983	\$2,964,464	238.3%
License revenue	7,500	1,000	6,500	650.0%
Net revenue	4,215,947	1,244,983	2,970,964	238.6%

Edgar Filing: INNOVUS PHARMACEUTICALS, INC. - Form 10-Q

OPERATING EXPENSE:				
Cost of product sales	849,055	383,057	465,998	121.7%
Research and development	18,246	3,892	14,354	100.0%
Sales and marketing	3,243,087	285,011	2,958,076	1,037.9%
General and administrative	2,886,898	2,233,309	653,589	29.3%
Total operating expense	6,997,286	2,905,269	4,092,017	140.8%
LOSS FROM OPERATIONS	(2,781,339)	(1,660,286)	(1,121,053)	67.5%
OTHER INCOME (EXPENSE):				
Interest expense	(667,609)	(2,251,250)	1,583,641	(70.3)%
Loss on extinguishment of debt	(304,828)	-	(304,828)	100.0%
Other income (expense), net	(822)	1,876	(2,698)	(143.8)%
Fair value adjustment for contingent consideration	126,154	(22,334)	148,488	(664.9)%
Change in fair value of derivative liabilities	(48,193)	(1,983,315)	1,935,122	(97.6)%
Total other expense, net	(895,298)	(4,255,023)	3,359,725	(79.0)%
LOSS BEFORE PROVISION FOR INCOME TAXES	(3,676,637)	(5,915,309)	2,238,672	(37.8)%
TAXES				
Provision for income taxes	3,200	-	3,200	100.0%
NET LOSS	\$(3,679,837)	\$(5,915,309)	2,235,472	(37.8)%

Table of Contents

Net Revenue

We recognized net revenue of approximately \$2.0 million and \$4.2 million for the three and six months ended June 30, 2017, respectively, compared to \$1.0 million and \$1.2 million for the three and six months ended June 30, 2016, respectively. The increase in revenue in 2017 was primarily the result of the product sales generated through the sales and marketing platform acquired in the Beyond Human® asset acquisition in March 2016. The increase was also due to the launch of UriVarx™ at the end of the fourth quarter 2016 and ProstaGorx™. These new product launches generated net revenue of approximately \$973,000 and \$1.5 million during the three and six months ended June 30, 2017. The increase was also attributed to an increase in sales of Vesele® and Sensum+®, which generated net revenue of approximately \$639,000 and \$1.6 million for Vesele®, and \$185,000 and \$554,000 for Sensum+® during the three and six months ended June 30, 2017, respectively, compared to approximately \$573,000 for Vesele® and \$8,000 for Sensum+® during the three and six months ended June 30, 2016, respectively. The increase in net revenue from the sale of products through the Beyond Human® sales and marketing platform was offset by decreases in our other existing product sales channels to major retailers and wholesalers as we concentrated our sales efforts and resources on integrating our existing products into the Beyond Human® sales and marketing platform to increase our gross margin. The decreases in existing product sales channels resulted in net revenue from the Zestra® products decreasing approximately \$5,000 and \$61,000 during the three and six months ended June 30, 2017, respectively, when compared to the same period in 2016. We signed an exclusive license and distribution agreement in November 2016 for the sale of Zestra® and Zestra Glide® in South Korea and, in March 2017, we shipped the initial order under such agreement resulting in net revenue of \$60,000 during the six months ended June 30, 2017. In the second quarter of 2017, we entered into two additional exclusive license and distribution agreements which we expect will lead to an increase in product sales of Zestra® and Zestra Glide® through our Ex-U.S. sales channel in 2017.

Cost of Product Sales

We recognized cost of product sales of approximately \$409,000 and \$849,000 for the three and six months ended June 30, 2017, respectively, compared to \$263,000 and \$383,000 for the three and six months ended June 30, 2016, respectively. The cost of product sales includes the cost of inventory, shipping and royalties. The increase in cost of product sales is a result of higher shipping costs due to an increase in the number of units shipped. The increase in the gross margin to 80% in 2017 compared to 69% in 2016 is due to the higher margins earned on the increased volume of our product sales through the Beyond Human® sales and marketing platform. The increased margin in 2017 is also due to fewer sales when compared to 2016 through our retail and wholesale sales channels, which have lower margins.

Research and Development

We recognized research and development expense of approximately \$15,000 and \$18,000 for the three and six months ended June 30, 2017, respectively, compared to \$4,000 for the three and six months ended June 30, 2016. The research and development expense includes salary and the related health benefits for an employee who was terminated in January 2017, as well as, costs for stability testing and other development related costs for our products.

Sales and Marketing

We recognized sales and marketing expense of approximately \$1.6 million and \$3.2 million for the three and six months ended June 30, 2017, respectively, compared to \$250,000 and \$285,000 for the three and six months ended June 30, 2016, respectively. Sales and marketing expense during the six months ended June 30, 2017 consist primarily of print advertisements and sales and marketing support. The increase in sales and marketing expense during the three and six months ended June 30, 2017 when compared to the same period in 2016 is due to the increase in the number of products integrated into the Beyond Human® sales and marketing platform, the increase in print and online media

advertisements of our existing products through the Beyond Human® platform, as well as, the costs of our third-party customer service call center due to the higher volume of sales orders received as a result of the Beyond Human® asset acquisition.

-30-

Table of Contents

General and Administrative

We recognized general and administrative expense of approximately \$1.2 million and \$2.9 million for the three and six months ended June 30, 2017, respectively, compared to \$946,000 and \$2.2 million for the three and six months ended June 30, 2016. General and administrative expense consists primarily of investor relation expense, legal, accounting, public reporting costs and other infrastructure expense related to the launch of our products. Additionally, our general and administrative expense includes professional fees, insurance premiums and general corporate expense. The increase is primarily due to the increase in merchant processing fees due to increased credit card sales volume and increased payroll and related costs due to the increase in headcount when compared to 2016. The increase was offset by a decrease in stock-based compensation to employees, directors and consultants of approximately \$322,000 and \$482,000, respectively, during the three and six months ended June 30, 2017 compared to 2016.

Other Income and Expense

We recognized interest expense of approximately \$110,000 and \$668,000 for the three and six months ended June 30, 2017, respectively, compared to \$1.9 million and \$2.3 million for the three and six months ended June 30, 2016, respectively. Interest expense primarily includes interest related to our debt and amortization of debt discounts (see Note 5 to the accompanying condensed consolidated financial statements included elsewhere in this Quarterly Report). Due to the shares, warrants and cash discounts provided to our lenders, the effective interest rate is significantly higher than the coupon rate. The decrease in interest expense during the three and six months ended June 30, 2017 is due to the larger amount of debt discount amortization in 2016 compared to 2017 as a result of the convertible debt and note payable financings completed in 2016 and the repayment of the convertible debt in March 2017.

We recognized a loss on extinguishment of debt of approximately \$305,000 during the six months ended June 30, 2017. The loss on debt extinguishment was the result of the required prepayment of the 2016 Notes from the cash proceeds received through the public equity offering in March 2017. Under the terms of the 2016 Notes, we were required to prepay the outstanding principal and interest of the convertible debentures with the cash proceeds received from an equity offering with an offering price less than the current conversion price of the debentures of \$0.25 per share, as well as incur a 10% prepayment penalty. As a result of the prepayment, the remaining unamortized debt discount of approximately \$416,000, the prepayment penalty of \$127,000 and the extinguishment of the embedded conversion feature derivative liability of \$238,000 were recorded as a loss on debt extinguishment during the six months ended June 30, 2017.

We recognized a gain from the fair value adjustment for contingent consideration of approximately \$99,000 and \$126,000 for the three and six months ended June 30, 2017, respectively, compared to a loss of \$17,000 and \$22,000 for the three and six months ended June 30, 2016, respectively. Fair value adjustment for contingent consideration consists primarily of the decrease in the fair value of the remaining contingent ANDA shares of common stock issuable to individual members of Novalere Holdings, LLC in connection with our acquisition in 2015 totaling approximately \$20,000 and the decrease in the royalty contingent consideration to Semprae of approximately \$106,000 (see Note 3 to the accompanying condensed consolidated financial statements included elsewhere in this Quarterly Report).

We recognized a gain (loss) from the change in fair value of derivative liabilities of approximately \$3,000 and \$(48,000) for the three and six months ended June 30, 2017, respectively, compared a loss from the change in fair value of derivative liabilities of \$2,041,000 and \$1,983,000 for the three and six months ended June 30, 2016, respectively. Change in fair value of derivative liabilities primarily includes the change in the fair value of the warrants and embedded conversion features classified as derivative liabilities. The loss on change in fair value of

derivative liabilities during the six months ended June 30, 2017 is primarily due to the increase in our stock price from December 31, 2016 through the date of conversion of certain of the convertible debentures in 2017, which resulted in the fair value of the embedded conversion features at the conversion date to be higher than the fair value at December 31, 2016.

Net Loss

Net loss for the three and six months ended June 30, 2017 was approximately \$(1.1 million) or \$(0.01) basic and diluted net loss per share and \$(3.7 million) or \$(0.02) basic and diluted net loss per share, respectively, compared to a net loss for the same periods in 2016 of \$(4.4 million) or \$(0.05) basic and diluted net loss per share and \$(5.9 million) or \$(0.08) basic and diluted net loss per share, respectively.

Table of Contents

Liquidity and Capital Resources

Historically, we have funded losses from operations through the sale of equity and the issuance of debt instruments. Combined with revenue, these funds have provided us with the capital to operate our business, to sell and support our products, attract and retain key personnel, and add new products to our portfolio. To date, we have experienced net losses each year since our inception. As of June 30, 2017, we had an accumulated deficit of approximately \$32.8 million and a working capital deficit of \$1.0 million.

As of June 30, 2017, we had approximately \$1.8 million in cash. Although no assurances can be given, we may raise additional capital through the sale of equity or debt securities. We expect, however, that our existing capital resources, revenue from sales of our products and upcoming new product launches and sales milestone payments from the commercial partners signed for our products, and equity instruments available to pay certain vendors and consultants, will be sufficient to allow us to continue our operations, commence the product development process and launch selected products through at least the next 12 months. In addition, our CEO, who is also a significant shareholder, has deferred the remaining payment of his salary earned thru June 30, 2016 totaling \$1,036,315 for at least the next 12 months.

Our actual needs will depend on numerous factors, including timing of introducing our products to the marketplace, our ability to attract additional Ex-U.S. distributors for our products and our ability to in-license in non-partnered territories and/or develop new product candidates. In addition, we continue to seek new licensing agreements from third-party vendors to commercialize our products in territories outside the U.S., which could result in upfront, milestone, royalty and/or other payments.

We may raise additional capital through the sale of debt or equity securities to provide additional working capital, for further expansion and development of our business, and to meet current obligations, although no assurances can be given. If we issue equity or convertible debt securities to raise additional funds, our existing stockholders may experience substantial dilution, and the newly issued equity or debt securities may have more favorable terms or rights, preferences and privileges senior to those of our existing stockholders. If we raise funds by incurring additional debt, we may be required to pay significant interest expense and our leverage relative to our earnings or to our equity capitalization may increase. Obtaining commercial loans, assuming they would be available, would increase our liabilities and future cash commitments and may impose restrictions on our activities, such as financial and operating covenants. Further, we may incur substantial costs in pursuing future capital and/or financing transactions, including investment banking fees, legal fees, accounting fees, printing and distribution expense and other costs. We may also be required to recognize non-cash expense in connection with certain securities we may issue, such as convertible notes and warrants, which would adversely impact our financial results. We may be unable to obtain financing when necessary as a result of, among other things, our performance, general economic conditions, conditions in the pharmaceuticals industries, or our operating history. In addition, the fact that we are not and have never been profitable could further impact the availability or cost to us of future financings. As a result, sufficient funds may not be available when needed from any source or, if available, such funds may not be available on terms that are acceptable to us. If we are unable to raise funds to satisfy our capital needs when needed, then we may need to forego pursuit of potentially valuable development or acquisition opportunities, we may not be able to continue to operate our business pursuant to our business plan, which would require us to modify our operations to reduce spending to a sustainable level by, among other things, delaying, scaling back or eliminating some or all of our ongoing or planned investments in corporate infrastructure, business development, sales and marketing and other activities, or we may be forced to discontinue our operations entirely.

The Company's principle debt instruments include the following:

February 2016 Note Payable

On February 24, 2016, the Company and SBI Investments, LLC, 2014-1 (“SBI”) entered into an agreement in which SBI loaned us gross proceeds of \$550,000 pursuant to a purchase agreement, 20% secured promissory note and security agreement (“February 2016 Note Payable”), all dated February 19, 2016 (collectively, the “Finance Agreements”). Pursuant to the Finance Agreements, the principal amount of the February 2016 Note Payable was \$550,000 and the interest rate thereon is 20% per annum. We began to pay principal and interest on the February 2016 Note Payable on a monthly basis beginning on March 19, 2016 for a period of 24 months and the monthly mandatory principal and interest payment amount thereunder is \$28,209. The monthly amount shall be paid by us through a deposit account control agreement with a third-party bank in which SBI shall be permitted to take the monthly mandatory payment amount from all revenue received by us from the Beyond Human® assets in the transaction. The maturity date for the February 2016 Note Payable is February 19, 2018. The February 2016 Note Payable is secured by SBI through a first priority secured interest in all of the Beyond Human® assets acquired by us in the transaction including all revenue received by us from these assets. The principal balance of the February 2016 Note Payable as of June 30, 2017 is \$209,040.

Table of Contents

December 2016 and January 2017 Notes Payable

On December 5, 2016 and January 19, 2017, we entered into a securities purchase agreement with three unrelated third-party investors in which the investors loaned us gross proceeds of \$650,000 pursuant to 5% promissory notes. The notes have an OID of \$65,000 and requires payment of \$715,000 in principal upon maturity. The notes bear interest at the rate of 5% per annum and the principal amount and interest are payable at maturity on October 4, 2017 and November 18, 2017. In connection with the notes, we issued the investors restricted shares of common stock totaling 1,441,111. The fair value of the restricted shares of common stock issued was based on the market price of our common stock on the date of issuance of the notes.

Net Cash Flows

	Six Months Ended June 30, 2017	Six Months Ended June 30, 2016
Net cash (used in) provided by operating activities	\$(969,292)	\$256,152
Net cash used in investing activities	(8,048)	(6,565)
Net cash provided by (used in) financing activities	1,972,040	(107,355)
Net change in cash	994,700	142,232
Cash at beginning of period	829,933	55,901
Cash at end of period	\$1,824,633	\$198,133

Operating Activities

For the six months ended June 30, 2017, cash used in operating activities was approximately \$969,000, consisting primarily of the net loss for the period of approximately \$3.7 million, which was primarily offset by non-cash common stock, restricted stock units and stock options issued for services and compensation of approximately \$742,000, amortization of debt discount of \$601,000, loss on debt extinguishment of \$305,000, change in fair value of derivative liabilities of \$48,000, and amortization of intangible assets of \$315,000. The non-cash expense was offset with the gain on change in fair value of contingent consideration of approximately \$126,000. Additionally, working capital changes consisted of cash increases of approximately \$815,000 related to a decrease in accounts receivable from cash collections from customers of approximately \$8,000, \$277,000 related to an increase in accrued compensation, \$407,000 related to an increase in accounts payable and accrued expense, \$88,000 related to a decrease in prepaid expense and other current assets, \$36,000 related to an increase in deferred revenue and customer deposits and \$13,000 related to a decrease in inventories, partially offset by a cash decrease related to accrued interest of \$14,000. The increase in net cash used in operating activities from 2016 was mainly due to expanding our operations, including hiring additional personnel, commercialization and marketing activities related to our existing products and those acquired in 2016.

Investing Activities

For the six months ended June 30, 2017, cash used in investing activities was approximately \$8,000 which consisted of the purchase of property and equipment for our corporate office location compared to \$7,000 for 2016.

Financing Activities

For the six months ended June 30, 2017, cash provided by financing activities was approximately \$2.0 million, consisting primarily of the net proceeds from the public equity offering of \$3.3 million and notes payable of \$150,000, offset by the repayment of convertible debentures of approximately \$1.2 million, notes payable of \$139,000, and the prepayment penalty on the repayment of the convertible debentures of \$127,000. Cash used in financing activities in 2016 was primarily related to net proceeds from notes payable and convertible debentures of approximately \$417,000 and proceeds from short-term loans payable of \$22,000, offset by the repayment of notes payable and short-term loans payable of \$408,000, payment of financing costs in connection with convertible debentures of \$19,000, and the repayment of the related-party line of credit convertible debenture of \$119,000.

Table of Contents

Critical Accounting Policies and Estimates

On January 1, 2017, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-15, Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments. We elected to early adopt ASU 2016-15 and, as a result, the prepayment penalty of \$127,247 in connection with the extinguishment of the 2016 Notes (see Note 5 in the accompanying condensed consolidated financial statements) in March 2017 is classified as a financing cash outflow in the accompanying condensed consolidated statement of cash flows for the six months ended June 30, 2017. The adoption of this ASU did not have a material impact on our condensed consolidated financial position, results of operations and related disclosures and had no other impact to the accompanying condensed consolidated statement of cash flows for the six months ended June 30, 2017 and 2016.

For the six months ended June 30, 2017, there were no other material changes to the “Critical Accounting Policies” discussed in Part II, Item 7 (Management’s Discussion and Analysis of Financial Condition and Results of Operations) of our Annual Report on Form 10-K for the year ended December 31 2016.

Off- Balance Sheet Arrangements

None.

Recent Accounting Pronouncements

See Note 1 to our condensed consolidated financial statements included in this Quarterly Report.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures.

As of June 30, 2017, we evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")).

Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2017, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including chief executive officer and vice president, finance, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, but not absolute, assurance that the objectives of the disclosure controls and procedures are met. The design of any disclosure control and procedure also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in internal control over financial reporting.

During the quarter ended June 30, 2017, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

-34-

Table of Contents

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the normal course of business, we may be a party to legal proceedings. We are not currently a party to any legal proceedings.

ITEM 1A. RISK FACTORS

The risks described in Part I, Item 1A, Risk Factors, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, could materially and adversely affect our business, financial condition and results of operations. These risk factors do not identify all of the risks that we face. Our business, financial condition and results of operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial. There have been no material changes to the “Risk Factors” section included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

For the three months ended June 30, 2017, we issued 418,349 shares of our common stock valued at \$182,000 in exchange for services under existing consulting and service agreements with third parties.

Each of the securities were offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder and/or Section 3(a)(9) of the Securities Act. Each of the investors represented that it was an "accredited investor" as defined in Regulation D under the Securities Act.

Use of Proceeds from the Sale of Registered Securities

On March 15, 2017, our registration statement on Form S-1 (File No. 333-215851) was declared effective by the SEC for our public offering pursuant to which we sold an aggregate of 25,666,669 shares of our common stock at an offering price of \$0.15 per share. There has been no material change in our use of proceeds from our public offering as described in our final prospectus filed with the SEC on March 17, 2017 pursuant to Rule 424(b).

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

See the Exhibit Index immediately following the signature page of this report.

-35-

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Innovus
Pharmaceuticals,
Inc.
(Registrant)

Date: August 14, 2017 /s/ Bassam Damaj
Bassam Damaj,
Ph.D.
President, Chief
Executive Officer
and Director
(Principal
Executive Officer)

/s/ Rauly Gutierrez
Rauly Gutierrez,
CPA
Vice President,
Finance
(Principal Financial
Officer)

Table of Contents

INDEX TO EXHIBITS

Exhibit No.	Description
<u>4.1</u>	Form of Securities Purchase Agreement filed as Exhibit 4.1 to the Registrant's report on Amendment No. 1 to Form S-1 filed with the SEC on March 13, 2017 and incorporated herein by reference.
<u>4.2</u>	Form of Series A and Series B Warrant filed as Exhibit 4.2 to the Registrant's report on Amendment No. 1 to Form S-1 filed with the SEC on March 13, 2017 and incorporated herein by reference.
<u>4.3</u>	Form of Placement Agent Warrant filed as Exhibit 4.3 to the Registrant's report on Amendment No. 1 to Form S-1 filed with the SEC on March 13, 2017 and incorporated herein by reference.
<u>10.1</u>	Employment Agreement, dated as of September 23, 2016 by and between Innovus Pharmaceuticals, Inc. and Rauly Gutierrez (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed April 14, 2017).
<u>31.1*</u>	Certification of Bassam Damaj, Ph.D., principal executive officer, pursuant to Rule 13-a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
<u>31.2*</u>	Certification of Rauly Gutierrez, CPA, principal financial officer, pursuant to Rule 13-a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
<u>32.1**</u>	Certification of Bassam Damaj, Ph.D., principal executive officer, and Rauly Gutierrez, CPA, principal financial officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

*

Filed herewith.

**

This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation by reference language of such filing.